

## Gut-Brain Nexus: Mapping Multi-Modal Links to Neurodegeneration at Biobank Scale

Mohammad Shafieinouri<sup>1</sup>, Samantha Hong<sup>1</sup>, Artur Schuh<sup>2,3</sup>, Mary B. Makarious<sup>1,4</sup>, Rodrigo Sandon<sup>1</sup>, Paul Suhwan Lee<sup>1</sup>, Emily Simmonds<sup>5</sup>, Hirotaka Iwaki<sup>1,4</sup>, Gracelyn Hill<sup>1,4</sup>, Cornelis Blauwendraat<sup>1,6</sup>, Valentina Escott-Price<sup>5,7</sup>, Yue A. Qi<sup>1</sup>, Alastair J. Noyce<sup>8</sup>, Armando Reyes-Palomares<sup>9</sup>, Hampton L. Leonard<sup>1,4</sup>, Malu Tansey<sup>10,11</sup>, Anant Dadu<sup>1,4</sup>, Faraz Faghri<sup>1,4</sup>, Andrew Singleton<sup>1,6</sup>, Mike A. Nalls<sup>1,4</sup>, Kristin S. Levine<sup>1,4, #</sup>, Sara Bandres-Ciga<sup>1, #</sup>

### Affiliations

1 - Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA 20892.

2 - Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

3 - Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

4 - DataTecnica LLC, Washington, DC, USA 20037.

5 - UK Dementia Research Institute (UK DRI) at Cardiff University, Cardiff, UK

6 - Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA

7 - Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK

8 - Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

9 - Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga, Málaga, Spain

10 - Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, FL, USA. mgtansey@ufl.edu.

11 - Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida Health, Gainesville, FL, USA.

# Contributed equally

### Key words:

Alzheimer's disease; Parkinson's disease, endocrine, nutritional, metabolic, digestive system, polygenic risk score, interaction, risk, multi-modal classification, proteomics, genetics, prediction.

### Corresponding authors:

Mohammad Shafieinouri

Center for Alzheimer's and Related Dementias, National Institutes of Health  
Bethesda, MD, USA 20892.

Email: [mohammad.shafieinouri@nih.gov](mailto:mohammad.shafieinouri@nih.gov)

Sara Bandres-Ciga

Center for Alzheimer's and Related Dementias (CARD), NIA, NIH

Bethesda, MD, USA 20892

Email: [sara.bandresciga@nih.gov](mailto:sara.bandresciga@nih.gov)

**Acknowledgements:**

This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000534, as well as the National Institute of Neurological Disorders and Stroke. This work was also supported by the Dementia Research Institute [UKDRI supported by the Medical Research Council (UKDRI-3003), Alzheimer's Research UK, and Alzheimer's Society], Welsh Government, Joint Programming for Neurodegeneration (MRC: MR/T04604X/1), Dementia Platforms UK (MRC: MR/L023784/2) and MRC Centre for Neuropsychiatric Genetics and Genomics (MR/L010305/1). This research has been conducted using the UK Biobank Resource under application number 33601. We want to acknowledge the participants and investigators of the FinnGen study and thank them for their hard work and generosity. This study makes use of anonymised data held in the Secure Anonymised Information Linkage (SAIL) Databank. This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research. We wish to acknowledge the collaborative partnership that enabled acquisition and access to the de-identified data, which led to this output. The collaboration was led by the Swansea University Health Data Research UK team under the direction of the Welsh Government Technical Advisory Cell (TAC) and includes the following groups and organizations: the SAIL Databank, Administrative Data Research (ADR) Wales, Digital Health and Care Wales (DHCW), Public Health Wales, NHS Shared Services Partnership (NWSSP) and the Welsh Ambulance Service Trust (WAST). All research conducted has been completed under the permission and approval of the SAIL independent Information Governance Review Panel (IGRP) project number 0998. We would like to acknowledge the participants and investigators of the FinnGen study. The FinnGen study is a large-scale genomics initiative that has analyzed over 500,000 Finnish biobank samples and correlated genetic variation with health data to understand disease mechanisms and predispositions. The project is a collaboration between research organizations and biobanks within Finland and international industry partners (1).

**Author contributions:**

M.S., S.B.C and K.S.L. designed the study; M.S, E.S., K.S.L., H.L.L., C.B., H.I, and M.A.N. acquired and processed data; M.S, E.S., and K.S.L. analyzed data; all authors contributed to interpreting data and writing and editing of the manuscript.

**Declaration of interests:**

K.S.L., H.L.L., H.I., M.B.M., and M.A.N.'s participation in this project was part of a competitive contract awarded to Data Technica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board at

Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc.

### Data and Code Availability

This paper analyzes existing, publicly available data. In addition, complete summary statistics describing these data/processed datasets derived from these data have been deposited in the supplementary materials connected to this publication and are publicly available as of the date of publication.

### Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are influenced by genetic and environmental factors. Using data from UK Biobank, SAIL Biobank, and FinnGen, we conducted an unbiased, population-scale study to: 1) Investigate how 155 endocrine, nutritional, metabolic, and digestive system disorders are associated with AD and PD risk prior to their diagnosis, considering known genetic influences; 2) Assess plasma biomarkers' specificity for AD or PD in individuals with these conditions; 3) Develop a multi-modal classification model integrating genetics, proteomics, and clinical data relevant to conditions affecting the gut-brain axis. Our findings show that certain disorders elevate AD and PD risk before AD and PD diagnosis including: insulin and non-insulin dependent diabetes mellitus, noninfective gastro-enteritis and colitis, functional intestinal disorders, and bacterial intestinal infections, among others. Polygenic risk scores revealed lower genetic predisposition to AD and PD in individuals with co-occurring disorders in the study categories, underscoring the importance of regulating the gut-brain axis to potentially prevent or delay the onset of neurodegenerative diseases. The proteomic profile of AD/PD cases was influenced by comorbid endocrine, nutritional, metabolic, and digestive systems conditions. Importantly, we developed multi-modal prediction models integrating clinical, genetic, proteomic and demographic data, the combination of which performs better than any single paradigm approach in disease classification. This work aims to illuminate the intricate interplay between various physiological factors involved in the gut-brain axis and the development of AD and PD, providing a multifactorial systemic understanding that goes beyond traditional approaches.

## Introduction

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders (2),(3) and cumulatively affect over 400 million individuals worldwide (4),(5). Though significant genetic risk factors for AD and PD have been identified, sporadic and late-onset forms are thought to be caused by a complex interplay between genetic (6),(7) and environmental (8),(9) factors. This interplay underscores the imperative to explore a multitude of variables across bodily systems to comprehend their contributions to the etiology of AD/PD (10),(11).

Increasingly, research in neurodegeneration emphasizes the role of gut-brain axis health in neurodegeneration risk (12), (13). The gut-brain axis is a complex communication network that links the gastrointestinal tract and the central nervous system. This bidirectional system, including neural pathways, hormonal signaling, and immune mechanisms, facilitates constant interactions between the brain, digestive, endocrine, metabolic systems and nutritional status. Conditions that impact the gut-brain axis include digestive system disorders (14), endocrine pathway disorders (15), (16), nutritional deficiencies (17), (18), and metabolic traits (19).

Endocrine disorders, such as thyroid hormone imbalances, have been linked to AD and PD (16),(20), with conditions like hypothyroidism and subclinical hyperthyroidism being associated with dementia risk (21) and both hypo- and hyperthyroidism being associated with increasing PD risk (16). Metabolic disorders, particularly diabetes, are also related to neurodegenerative disease risk. An increased severity of diabetes is associated with a higher risk of PD (22),(23) and type 2 diabetes is a recognized risk factor for AD (24). Consequently, antidiabetic medications are being explored as potential treatments for AD and PD (25). Additionally, nutritional deficiencies such as low vitamin D levels are more prevalent in AD and PD patients (26). Digestive disorders have been observed to precede PD (27) or be significantly associated with an increased risk for dementia (28). These are just a few examples of factors contributing to the gut-brain axis health and their influence on neurodegeneration.

Understanding the connection between disorders of the gut-brain axis and neurodegeneration can provide useful insights into therapeutic interventions, with major implications for prevention and disease prognosis. In this study, we perform a large biobank-scale characterization of the impact that disorders affecting the gut-brain axis and related to endocrine, nutritional, metabolic, and digestive systems have

on the risk of AD and PD. Utilizing data from the UK Biobank, SAIL, and FinnGen, we conducted a population-scale, unbiased assessment that aimed to: 1) Investigate the association between 155 diagnoses related to endocrine, nutritional, metabolic, and digestive system disorders and the risk of AD and PD, while also accounting for established genetic factors known to influence the development of these conditions; 2) Evaluate the specificity of plasma biomarkers associated with AD or PD when individuals have these co-occurring conditions; 3) Develop a multi-modal classification model combining all these data modalities.

## Methods

This study utilizes data from three biobanks: the UK Biobank (UKB), FinnGen, and the Secure Anonymized Information Linkage (SAIL) (See [Figure 1](#) for an workflow rationale of this study).

### *UK Biobank*

The UKB data, accessed via DNAnexus under application number 33601, includes electronic health records of approximately 502,367 individuals, single nucleotide polymorphism (SNP) data of 487,279 individuals, and proteomic (Olink) data of 52,705 individuals (<https://ukbiobank.dnanexus.com>) (accessed on May 2023). The control group for the UKB dataset consisted of a subset of 352,610 individuals who have not been diagnosed with any neurodegenerative disease condition ([Supplementary Table 1](#)) and have no family history AD and PD diagnosis. For our approach, related individuals were filtered out from further analyses based on a kinship coefficient greater than 0.0884, and only individuals of European descent were selected for this study, based on field ID 22006, who self-identified as 'White British' and confirmed through principal component (PC) analysis of the genotyping data to avoid potential confounding effects. We lacked a sufficient number of individuals with non-European ancestry to conduct a meaningful assessment. Our final dataset included 409,520 individuals of European ancestry. Endocrine, nutritional, metabolic, and digestive disorders, as well as AD and PD diagnosis, were derived from ICD-10 (International Classification of Diseases, 10th Revision) codes. The AD cohort was obtained from the G30 and F00 ICD-10 codes in the UKB, and the PD cohort was obtained from the G20 ICD-10 code. We excluded any individuals who had received an ICD-10 diagnosis for endocrine, nutritional, metabolic, and digestive disorders before January 1st, 1999, and right-censored any individuals who received an ICD-10 diagnosis after being diagnosed with AD or PD. Furthermore, any ICD-10 code with fewer than 5 cases was excluded from the analysis. Demographic characteristics are shown in [Supplementary Table 2](#).

### *SAIL Databank*

The Secure Anonymised Information Linkage (SAIL) databank is a virtual platform providing anonymized medical data of the population in Wales (29). Diagnoses in SAIL are sourced from the Patient Episode Database for Wales (PEDW), records from clinicians and hospital staff, the Welsh Longitudinal General Practitioner dataset (WLGP), records from primary care physicians of diagnoses, treatments, symptoms, and referrals. Demographic information such as sex, age, address, and death were obtained from the Welsh Demographic Services Database (WDSD) and WLGP. Individuals with missing age or sex data and those without a Welsh address were excluded from further analysis.

Diagnoses were identified in the PEDW using ICD-10 codes and in the WLGP using NHS read codes (CVT2,3). Neurodegenerative disorders from the outpatient data (OPDW) were excluded due to their minimal representation of dementia cases (only 0.1%) and the absence of reliable diagnosis dates. Similarly, dementia diagnoses from death records (ADDES) were not included due to inaccurate diagnosis dates. This study covered the period from January 1, 1999, to December 31, 2018. For inclusion, individuals were required to have been alive at the start of 1999 and to have been at least 45 years old on January 1, 1999.

### *FinnGen Biobank*

The FinnGen study is a large-scale genomics initiative that has analyzed over 500,000 Finnish biobank samples and correlated genetic variation with health data to understand disease mechanisms and predispositions. The project is a collaboration between research organisations and biobanks within Finland and international industry partners (1).

FinnGen provides survival analyses across numerous clinical endpoints. The hazard ratios are adjusted for sex and year of birth. FinnGen bases the calculation of these hazard ratios on a wide array of clinical endpoints defined through data from nationwide registries, including, but not limited to, Statistics Finland [<https://finngen.gitbook.io/documentation/methods/endpoints>]. We downloaded the hazard ratios for AD/PD from FinnGen's Risteys R10 platform for AD using the G6\_AD\_WIDE category matching more closely the UKB grouping than G6\_AD [[https://r10.risteys.finngen.fi/endpoints/G6\\_AD\\_WIDE](https://r10.risteys.finngen.fi/endpoints/G6_AD_WIDE)] and for PD [[https://r10.risteys.finngen.fi/endpoints/G6\\_PARKINSON](https://r10.risteys.finngen.fi/endpoints/G6_PARKINSON)] to explore the putative impact of endocrine, digestive, metabolic, and nutritional disorders on the risk of of AD/PD prior to diagnosis. It is

important to note that not all ICD-10 codes used in our discovery phase in the UKB are represented in the FinnGen dataset. This discrepancy is perhaps due to the differences in health registries and data collection methodologies between the UKB and FinnGen biobanks.

### Polygenic Risk Score Analyses

Risk allele loci and beta values from GWAS summary statistics, specifically 23 risk predictors linked to AD risk from Kunkle 2019 and 90 risk predictors associated with PD from Nalls 2019, were used to estimate PRS for AD and PD respectively (30), (31). Each risk allele was assigned a weight based on the magnitude of its effect in the published studies, giving greater emphasis to alleles with higher risk estimates. Genetic variants were extracted for each individual from the UKB imputed data using the 'bgenix' package (32). The extracted variants were then converted to binary formats and used to compute the PRS score for each individual using PLINK 2.0 (33). Estimated profiles were then normalized to Z-scores based on a control reference.

### Cox Proportional Hazard Model

A Cox proportional hazards model was used to calculate the hazard ratio between risk for incident AD and PD and endocrine, nutritional, metabolic, and digestive system disorders. The disorders under study are represented as 155 ICD-10 codes ([Supplementary Table 3](#)). In this model, January 1st, 1999 was used as the cutoff date for the diagnosis of these conditions. Consequently, any individual diagnosed with these traits before January 1st, 1999 was excluded from the analysis. Logistic regressions and Cox proportional hazards models were adjusted for age, sex, the Townsend deprivation index, and 5 PCs to account for population stratification (precomputed in UKB only). Additionally, we conducted Time-Stratified Cox Regression Analysis, for which cohorts were divided into three strata based on ICD-10 codes: 1-5 years, 5-10 years, and 10-15 years prior to NDD diagnosis. ICD-10 diagnoses within the specified time periods were retained, while any ICD-10 codes outside of these time frames were converted to NaN.

### Polygenic Risk Score distribution for Alzheimer's disease and Parkinson's disease

A t-test was used to quantify the differences in the distribution of genetic alleles for AD or PD between individuals diagnosed only with AD or PD and individuals with an additional, significant ICD-10 diagnosis. This approach measures how much the cumulative effect of these alleles varies between the two groups. Additionally, it unveils the genetic risk profiles for AD and PD in both groups. By calculating and

comparing PRSs based on alleles associated with AD or PD, the analysis evaluates how the genetic predisposition to AD or PD is increased or decreased among those individuals diagnosed with one of the ICD-10 codes in addition to AD or PD. This comparison aids in understanding whether genetic risk for AD or PD is similar or distinct in the compared subgroups of study.

#### **Statistical Analysis accounting for the Impact of *APOE*, *LRRK2*, and *GBA1* risk variants.**

PRS analyses were adjusted for major genetic risk factors associated with AD and PD to determine if observed similarities or differences between AD/PD and the assessed ICD-10 codes could be attributed to pleiotropic effects. For AD, individuals homozygous for the 'C' allele at both *APOE* rs429358 and rs7412 were identified as having two copies of the *APOE*-ε4 allele, coded as '2', and one copy of the *APOE*-ε4 allele coded as '1' in our regression analysis to indicate a higher genetic risk. All other configurations were coded as '0'. For PD, we examined *LRRK2* at rs76904798, where homozygous 'C' alleles were coded as '0', and heterozygous and homozygous for 'T' alleles as '1'. Similarly, at rs34637584 (*LRRK2* G2019S), we applied '0' for homozygous 'G' alleles, and '1' for heterozygous and homozygous 'A' alleles. For *GBA1*, at rs35749011 (proxy for *GBA1* E326K), '0' was assigned to homozygous 'G' alleles, '1' to heterozygous and homozygous 'A' alleles, and at rs76763715 (*GBA1* N370S), '0' for homozygous 'T', and '1' for heterozygous and homozygous 'C' alleles.

#### **Interaction model for genetic risk across endocrine, metabolic, digestive system disorders and nutritional status**

We aimed to understand how the interplay between genetics underlying AD and PD risk and a clinical diagnosis for any investigated ICD-10 code could eventually influence an AD or PD diagnosis. A Generalized Linear Model (GLM) was used to account for more complex relationships, where the impact of genetic risk for AD or PD (as measured by PRS) might interact differently across the diagnoses under study represented by ICD-10 codes. The interaction term used in this model was: Z-score \* ICD-10 terms adjusted by sex, age and Townsend deprivation index.

#### **Proteomic Biomarker Data Analyses**

We aimed to explore differences in the levels of proteomic biomarkers associated with AD or PD between individuals with and without co-occurring ICD-10 code diagnoses related to endocrine, nutritional, metabolic, and digestive system disorders among UKB participants. For this purpose, we utilized data from the Pharma Proteome Project, which provides thousands of plasma protein

biomarkers in blood samples (<https://olink.com/news/uk-biobank-pharma-proteomics-project/>). In a cross-sectional analysis, we focused on baseline (Instance\_0) proteomics data, as it includes measurements for the largest number of individuals, encompassing data for 52,705 individuals (at the time of data access) and a total of 1,463 proteins ([Supplementary Table 4](#)). These biomarkers span across cardiometabolics, inflammation, neurology, and oncology markers.

We applied GLM to analyze 1,463 available biomarkers on AD and PD risk. The regressions were adjusted for age at recruitment, Townsend deprivation index, sex, and 5 PCs. Subsequently, we selected False Discovery Rate (FDR)-corrected significant proteomic biomarkers from the GLM results. Additionally, we compared the average levels of proteomic biomarkers in isolated cases of AD/PD with cases of AD/PD co-occurring with selected ICD-10 codes (found to be significantly associated with AD or PD risk before AD/PD diagnosis). We selected FDR-corrected significant proteomic biomarkers with an OR greater than 1 and applied a t-test to compare their average levels in the isolated cases of AD or PD and cases co-occurring with specific ICD-10 codes.

### **Multi-modal classification model for clinical, genetics and proteomics on Alzheimer's disease and Parkinson's disease risk**

To evaluate the role of endocrine, metabolic, digestive and nutritional status-related diagnoses in predicting AD or PD status, we developed a multi-modal classification model on a subset of the UK Biobank dataset. This subset included individuals with variables encompassing clinical diagnosis for endocrine, metabolic, digestive and nutritional status; biomarkers; demographic factors (age at recruitment, sex, and Townsend deprivation index); derived variables (Z score for the PRS); PCs; and *APOE* status for AD, or *LRRK2*/*GBA1* status for the PD model. The clinical diagnoses used in these models include the ICD-10 codes found to have significant HRs in UKB. We employed a machine learning approach to compare the predictive performance of various feature sets on AD/PD outcomes. These included genetics, clinical, proteomic, demographics (including sex, age at recruitment), and combinations thereof. Each dataset was independently analyzed using a Gradient Boosting Classifier, an ensemble learning method for classification tasks (<https://scikit-learn.org/stable/modules/generated/sklearn.ensemble.GradientBoostingClassifier.html>). We conducted hyperparameter tuning through GridSearchCV, optimizing for the number of estimators, learning rate, and maximum depth. For AD classification, the grid search adjusts XGBClassifier parameters including n\_estimators (2, 3, 5, 10, 15), learning\_rate (0.001, 0.01, 0.1), and max\_depth (3, 4,

5). For PD, it adjusts n\_estimators (300, 500), learning\_rate (0.005, 0.01), and max\_depth (1, 2, 3). Both models use nested cross-validation, optimizing based on ROC AUC. The dataset was downsampled to have an equal number of cases and controls, and then scaled using StandardScaler to ensure uniformity and prevent bias due to variance in measurement scales before classification training. Model performance was evaluated based on ROC AUC and balanced accuracy (BA) scores.

## Results

### **A prior diagnosis of certain endocrine, nutritional, metabolic, and digestive system related disorders is associated with increased risk for Alzheimer's disease and Parkinson's disease**

Cox regression models unraveled a total of 16 ICD-10 diagnoses to be significantly associated with the risk of AD ([Supplementary Table 5](#) and [Supplementary Figure 1](#)) in the UKB after correction for multiple comparisons (discovery cohort) that were also found to be significant in either SAIL, FinnGen biobanks, or both ([Table 1](#)). A diagnosis of hemorrhoids and perianal venous thrombosis was found to have a HR<1 for AD in all three datasets. This observation could potentially be due to the fact that a hospitalized diagnosis of hemorrhoids and perianal venous thrombosis could be an indication of other, more serious conditions linked to a high mortality rate, thus explaining the protective observed effect (34). The 15 other ICD-10 codes that were found to be significant have a HR>1, suggesting that being diagnosed with these conditions increases the risk for AD; these include amyloidosis; diseases of pulp and periapical tissues; disorders of lipoprotein metabolism and other lipidemias; disorders of mineral metabolism; gastritis and duodenitis; insulin-dependent, non-insulin-dependent, and unspecified diabetes mellitus; oesophagitis; other bacterial intestinal infections; other disorders of fluid, electrolyte and acid-base balance; other functional intestinal disorders; other noninfective gastro-enteritis and colitis; and volume depletion.

Of note, our analyses indicate significant associations between 7 disorders and the risk for PD ([Supplementary Table 6](#) and [Supplementary Figure 2](#)) that were replicated in either SAIL or FinnGen biobanks ([Table 2](#)). For PD, diverticular disease of the intestine, other diseases of the intestine, and other disorders of the peritoneum have HR<1 replicated in two datasets. Similarly to AD, individuals diagnosed with these conditions are not representative of the entire population due to the severity of these conditions and differential survival rates (36–39). The other 7 ICD-10 codes that had a HR>1 include

dyspepsia; insulin-dependent and non-insulin-dependent diabetes mellitus; and other functional intestinal disorders.

Additionally, we conducted a time-stratified cox regression analysis to evaluate whether the timing of diagnosis for the ICD-10 codes under study impacts HR values for AD or PD. We split the samples from UKB into three strata: 1-5 years, 5-10 years, and 10-15 years prior to AD/PD diagnosis. We then re-evaluated the HRs for AD and PD for the significant ICD-10 codes identified in the previous analysis ([Table 3](#) and [Table 4](#)).

The values and directions of the HRs in the stratified analysis show that the risk associated with each ICD-10 code is consistent across the three strata.

**Survival analysis indicates increased Alzheimer's disease and Parkinson's disease incidence in individuals with significant diagnosis of endocrine, nutritional, metabolic, and digestive system related disorders**

Using UKB data, we conducted survival analyses to explore the probabilities of an AD and PD diagnosis at a certain time interval. We generated Kaplan-Meier plots for the significantly associated ICD-10 codes as depicted in [Supplementary Figure 3](#) and [Supplementary Figure 4](#), respectively. At the beginning of the observation period, the survival probability starts at 1.0, indicating that all individuals diagnosed with an ICD-10 code are initially free from AD and PD. Over time, this probability diminishes as more individuals are diagnosed with AD or PD. The curves demonstrate the impact of specific ICD-10 code diagnosis on the likelihood of developing these neurodegenerative diseases. Notably, individuals with the significantly associated ICD-10 code diagnoses exhibited a higher incidence of AD and PD.

**Genetic susceptibility for Alzheimer's disease and Parkinson's disease is higher in isolated cases compared to those with co-occurring endocrine, nutritional, metabolic, and digestive disorders**

We compared the distribution of PRS in individuals diagnosed only with AD or PD versus those having concurrent AD/PD and any ICD-10 code diagnosis under study for samples from UKB only. Of note, some significant ICD-10 codes associated with AD included those pertaining to diabetes mellitus; other disorders of fluid, electrolyte, and acid-base balance; and obesity. Similarly, there were significant associations between diabetes mellitus, disorders of the peritoneum, and vitamin B group deficiencies, and PD. A comprehensive summary of these results is shown in [Supplementary Figure 5](#) and [Supplementary Figure 6](#).

For all significant t-tests, a lower average PRS was observed in individuals with co-occurring AD and another condition compared to individuals with only AD. For instance, in AD patients with a non-insulin-dependent diabetes mellitus diagnosis, our analysis revealed lower average PRS scores compared to individuals with only AD, either including or excluding *APOE* ( $t$ -test = -4.26,  $P$  = 2.3e-5 and  $t$ -test = -2.88,  $P$  = 4.01e-3, respectively). Similar trends were observed in individuals with AD and other bacterial intestinal infections (including *APOE*  $t$ -test = -2.31,  $P$  = 2.24e-02; excluding *APOE*  $t$ -test = -2.26,  $P$  = 2.54e-02), other disorders of pancreatic internal secretion (including *APOE*  $t$ -test = -2.17,  $P$  = 3.12e-02), oesophagitis (including *APOE*  $t$ -test = -3.08,  $P$  = 2.33e-02; excluding *APOE*  $t$ -test = -2.39,  $P$  = 1.78e-02), as well as gastritis and duodenitis (including *APOE*  $t$ -test = -2.83,  $P$  = 4.76e-03).

Of note, lower average PRS was observed for all significant t-tests in individuals with co-occurring PD and another condition compared to individuals with only PD. For instance, PD patients with other disorders of the peritoneum had a lower average PRS score than those with only PD ( $t$ -test = -3.00,  $P$  = 3.70e-03). Additionally, individuals with PD and other functional intestinal disorders ( $t$ -test = -2.08,  $P$  = 3.80e-02), insulin-dependent diabetes ( $t$ -test = -2.55,  $P$  = 1.29e-02), non-insulin dependent diabetes ( $t$ -test = -3.68,  $P$  = 2.52e-4), or a deficiency of other B group vitamins ( $t$ -test = -2.54,  $P$  = 1.23e-02) also had lower average PRS scores than individuals with only PD.

This result must be interpreted with caution, as there is potential for collider bias in our analysis. By selecting individuals with AD/PD, we are conditioning on these disorders, which are influenced by both the PRS for AD/PD and other risk factors, such as co-occurring endocrine, nutritional, metabolic, and digestive disorders. This conditioning can induce a spurious association between the PRS for AD/PD and these other risk factors, leading to the appearance of a lower average PRS in the group with AD/PD and co-occurring disorders. Essentially, this bias might make it seem as though lower genetic risk is linked to AD/PD in the presence of ICD-10 diagnoses, when in fact the relationship may be driven by the complex interplay of risk factors.

**The interplay between AD and PD cumulative known genetic effects and the risk for endocrine, nutritional, metabolic, and digestive systems disorders did not display any synergistic impact**

We did not identify significant synergistic interaction terms at a nominal  $P$ <0.05 and exhibiting an  $OR>1$  in either AD (see [Supplementary Table 7](#) and [Supplementary Table 8](#)) or PD (see [Supplementary Table 9](#)). This suggests that the combined occurrence of endocrine, nutritional, metabolic, or digestive system

related disorders does not lead to a synergic effect on AD/PD risk that surpasses the sum of their individual impacts.

### **The proteomic profile of individuals diagnosed with Alzheimer's disease and Parkinson's disease is influenced by comorbid endocrine, nutritional, metabolic, and digestive systems conditions**

Our analysis showed 22 proteomic biomarkers with notable differences in AD cases versus controls, alongside 156 proteins exhibiting significant distinctions in PD cases compared to controls after controlling for multiple comparisons ([Supplementary Table 10](#) and [Supplementary Table 11](#), respectively). We delved deeper into the levels of proteomic biomarkers, applying a t-test to juxtapose average levels between standalone cases of AD/PD and cases co-occurring with specific ICD-10 codes. After implementing FDR corrections, we found significant differences in proteomic biomarker levels in individuals with only AD/PD compared to individuals with AD/PD and co-occurring ICD-10 conditions. Specifically, we observed that 37 biomarkers displayed increased levels in AD cases with co-occurring ICD-10 diagnosis compared to isolated AD cases (see [Table 5](#)), while a total of five biomarkers demonstrated significant elevated levels in PD cases with accompanying conditions compared to standalone PD cases ([Table 6](#)). These findings hint at distinct associations between specific biomarkers and AD/PD, while others may be influenced by concurrent comorbidities.

### **Multi omics integration models based on clinical, genetic, and proteomic data improve accuracy to predict Alzheimer's disease and Parkinson's disease risk versus a single paradigm**

In our analysis, the combination of genetic, clinical, proteomic (controlling for multiple comparisons using Bonferroni correction), and demographic factors (including age at recruitment and gender) exhibited superior predictive performance for AD risk when compared to the individual data sets, with a test AUC of 0.9 and test balanced accuracy (BA) of 0.83. Curiously, the model combining genetic, proteomic, and demographic features (i.e. no clinical information) had a very similar test AUC of 0.89 and a test BA of 0.82. The best classifier using only one data attribute was the model that used only proteomic data for prediction with a test AUC of 0.87 and test BA of 0.79. The performance of each predictive model is shown in [Figure 2](#) and the metrics are listed in [Supplementary Table 12](#).

For PD, the integration of genetic, proteomic and demographic factors showcased heightened predictive efficacy with a test AUC of 0.80 and test BA of 0.73. For PD, addition of the clinical data did not improve the AUC and test BA of the model. The best classifier using only one data attribute was the

model that used demographics data (Age at recruitment, Sex and Townsend\_deprivation\_index), with a test AUC of 0.78 and a test BA of 0.72. The performance of each model for PD is shown in [Figure 3](#) and [Supplementary Table 13](#).

## Discussion

With the increasing prevalence of AD (40) and PD (41), it is imperative to enhance our understanding of the determinants that increase the risk for these common neurodegenerative diseases and most importantly, develop improved prediction models for early detection. Here, we have undertaken the most extensive biobank-scale omics study to date to assess the influence of main biological system disorders implicated in the gut-brain axis (including endocrine, nutritional, metabolic, and digestive-related conditions) preceding the diagnosis of AD and PD. The culmination of which is a multimodal classification model that combines clinical, genetics, and proteomics data enhancing the prediction accuracy of AD and PD.

In a large-scale and data driven manner, we demonstrate that certain endocrine, nutritional, metabolic, and digestive system related disorders are significantly associated with an increased risk of AD and/or PD prior to diagnosis. Of note, individuals with other non-infective gastroenteritis and colitis; oesophagitis; gastritis and duodenitis; disorders of fluid, electrolyte, and acid-base balance; pancreatic internal secretion disorders; and other functional intestinal disorders showed a higher likelihood of developing AD later in life. Recent literature has suggested the amplification of AD risk from disorders affecting the gut-brain axis, such as gastritis (42). Our results corroborate these findings and reveal additional, novel potential disorders of interest for further study, with replication across multiple datasets. In regards to PD, significant diagnoses associated with increased PD risk include other functional intestinal disorders, disorders of pancreatic internal secretion, and deficiency of other B group vitamins. The correlation between the deficiency of other B group vitamins and PD expands upon previous studies that have looked at other vitamin deficiencies, such as vitamin D (26), and warrants more research on the impact of nutritional deficiencies on neurodegenerative diseases.

Our study robustly demonstrates that the probability of developing AD/PD increases with certain co-occurring endocrine, metabolic, digestive, or nutritional conditions, corroborating the hypothesis that

a diagnosis affecting the gut-brain axis elevates the risk of AD/PD. We also show that risk of neurodegeneration persists up to 15 years before AD/PD onset with a co-occurring diagnosis of an endocrine, metabolic, digestive or nutritional disorder or trait. For example, having a diagnosis of other functional intestinal disorders results in an increased HR for both AD and PD in the periods 1-5, 5-10, and 10-15 years prior to AD/PD diagnosis.

In an effort to investigate genetic distinctions and potential etiological subtypes of AD and PD, we compared polygenic risk for AD and PD in individuals diagnosed only with AD or PD and individuals with AD or PD co-occurring with other endocrine, nutritional, metabolic, and digestive-related disorders. Of note, our study confirmed that individuals diagnosed with any type of diabetes mellitus in addition to AD or PD are shown to have a significant different PRS than individuals with AD or PD alone, in concordance with previous studies showing that diabetes is a risk factor for both AD and PD (43–45). For both AD and PD, comorbidity with any of the significant disorders affecting the gut-brain axis showed lower average PRS scores compared to those with only AD or PD. Our findings suggest that systemic health risk factors can more prominently account for one's disease risk in the absence of other genetic risk factors in patients with AD or PD, highlighting the importance of considering both genetic as well as other health factors in assessing the overall risk of developing AD and PD. Using diabetes as a positive control in our study, we found that individuals diagnosed with AD along with another disorder affecting the gut-brain axis, such as other bacterial intestinal infections and other functional intestinal disorders, result in a significantly lower average PRS score compared to individuals with only AD. This suggests that severe digestive conditions such as infections affecting the gut microbiome, independent of genetic risk, could increase the risk for AD as previously described (46). For PD, there existed a significant difference in PRS in individuals without vs. with other functional intestinal disorders and other disorders of the peritoneum, in concordance with previous studies suggesting an influence of disorders involving the gut-brain axis on PD (47).

In addition, our analysis revealed that the relationship between the genetic risk for AD/PD and many disorders of the endocrine, nutritional, metabolic and digestive systems resulted in a combined impact not significantly greater than the sum of their individual effects. These interactions are not synergistic, confirming the notion that known genetic risk factors included in the models under study for both AD and PD are independent from gastrointestinal and metabolic disorders, which highlights the importance of environmental factors in the development of both AD and PD. While both genetic and systemic health

disorders independently influence the risk of AD and PD, many disorders may not interact in a way that significantly amplifies this risk when combined.

Through our exploration of proteomics and AD/PD risk, we identified several promising candidates for AD/PD diagnosis. For instance, we found that for AD, the proteomic biomarker with the largest impact on disease was glial fibrillary acidic protein (GFAP), supporting previous literature findings that GFAP can serve as an indicator of AD pathology (48). However, the levels of GFAP were significantly decreased in samples with AD and a co-occurring ICD-10 code for gastritis and duodenitis or non-insulin dependent diabetes mellitus. For PD, in concordance with previous studies, we identified peroxiredoxin 1 (PRDX1) as a potential biomarker for disease (49). Again, the levels of PRDX1 were significantly decreased in PD cases and a coinciding ICD-10 code for insulin-dependent diabetes mellitus. These differences in biomarker levels between samples solely with AD/PD vs. samples with additional diagnoses highlight the influence of comorbidities on disease manifestation. Although longitudinal research would need to be conducted, our findings suggest that these biomarkers could serve as valuable diagnostic or prognostic tools for AD and PD, potentially enhancing early detection and disease management.

The inclusion of multiple features, integrating clinical data on digestive, endocrine, nutritional and metabolic disorders, genetic risk scores, and proteomic data in our prediction model, demonstrated superior performance in predicting both AD and PD compared to single-variable paradigms. Co-occurring diagnosis for conditions influencing the gut-brain axis do not seem to influence the predictability of neither AD nor PD as much as the other variables (demographic factors, biomarkers, and genetic status), but the fact that for both AD and PD the combination of data (clinical, genetic, proteomic, and demographic) produces a higher AUC for the ROC curve compared to single modalities underscores the value in including multiple facets of data in predictive models. Overall, these results from our models reveal the promising predictive capabilities of our constructed multi-modal classification models in identifying individuals at risk for AD/PD. The study suggests that the selected proteomic biomarkers, when combined with genetic and other demographic and clinical variables, serve as robust predictors. These predictors have the potential to significantly enhance prediction diagnostic accuracy for AD/PD. Our approach highlights the potential clinical utility of multi-omics in enhancing diagnostic accuracy, and further emphasizes the importance of considering other bodily systems when predicting the risk underlying neurodegenerative diseases.

Some overall limitations of our work include the use of solely ICD-10 codes for diagnosis, and not other additional assays, which may overlook undiagnosed cases, leading to a potential underestimation of the true impact of these disorders on AD/PD risk. Across datasets, the available diagnosis codes also differ causing further limitations in comparison and validation. Because individuals with AD often present with different cognitive, behavioral, and pathological features, diagnosis of AD is often difficult and inconsistent (50). Though we use the ICD-10 code to filter for AD in this study, it is possible for AD to be interchanged with dementia as diagnosing AD is difficult. The sample makeup across data sources can also be different. Since the UKB participants are volunteers who may have agreed to participate before reaching old age, the incidence of AD/PD may be different compared to the SAIL and FinnGen datasets. The cross-sectional nature of the data used to study biomarker associations may limit any causal inference. The SAIL and FinnGen datasets do not include proteomic data, preventing us from further validating our modeling efforts. The focus on samples of European ancestry constrains the generalizability of our findings to other populations from other genetic backgrounds. Future work needs to be done across different ancestral backgrounds to be globally representative.

Our study delves into the intricate interactions between clinical, genetic and proteomic data, culminating in the construction of a comprehensive multi-modal classification model. This pioneering endeavor aims to shed light on the nuanced interplay between various physiological factors playing a role on the gut-brain axis and the development of AD and PD, offering a multifactorial systemic understanding that transcends traditional approaches. Our integrated approach serves as a proof of concept, aligning with the expanding body of evidence that underscores the intricate etiological foundations of neurodegenerative diseases and holds promise for refining risk prediction models and devising targeted preventive strategies. This, in turn, propels our endeavors in elucidating clinical interventions aimed at addressing these debilitating conditions.

## **Figures**

**Figure 1** Study design

**Figure 2** Performance evaluation of multi-omics integration models using clinical, genetic, proteomic, and demographic data for Alzheimer's disease

**Figure 3** Performance evaluation of multi-omics integration models using clinical, genetic, proteomic, and demographic data for Parkinson's disease

## **Tables**

**[Table 1](#) Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with Alzheimer's disease risk**

**[Table 2](#) Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with Parkinson's disease risk**

**[Table 3](#) Time-stratified cox regression model for Alzheimer's disease**

**[Table 4](#) Time-stratified cox regression for Parkinson's disease**

**[Table 5](#) Proteomic biomarker comparison in isolated Alzheimer's disease cases vs. cases with digestive, endocrine, metabolic, and nutritional conditions**

**[Table 6](#) Proteomic biomarker comparison in isolated Parkinson's disease cases vs. cases with digestive, endocrine, metabolic, and nutritional conditions**

## **Supplementary Figures**

**[Supplementary Figure 1](#) Forest plots displaying the impact of digestive, endocrine, metabolic and nutritional conditions on Alzheimer's disease risk prior to diagnosis**

**[Supplementary Figure 2](#) Forest plots displaying the impact of digestive, endocrine, metabolic and nutritional conditions on Parkinson's disease risk prior to diagnosis**

**[Supplementary Figure 3](#) Survival analysis: Alzheimer's disease risk in individuals with digestive, endocrine, metabolic and nutritional related conditions**

**[Supplementary Figure 4](#) Survival analysis: Parkinson's disease risk in individuals with digestive, endocrine, metabolic and nutritional related conditions**

**[Supplementary Figure 5](#) Distribution of polygenic risk scores in individuals diagnosed only with Alzheimer's disease versus those diagnosed with concurrent Alzheimer's disease and significant digestive, endocrine, metabolic and nutritional conditions under study**

**[Supplementary Figure 6](#) Distribution of polygenic risk scores in individuals diagnosed only with Parkinson's disease versus those diagnosed with concurrent Parkinson's disease and significant digestive, endocrine, metabolic and nutritional conditions under study**

**[Supplementary Figure 7](#) Polygenic risk score distribution for Alzheimer's disease (all significant ICD-10 codes)**

**[Supplementary Figure 8](#) Polygenic risk score distribution for Parkinson's disease (all significant ICD-10 codes)**

## Supplementary Tables

[Supplementary Table 1](#) ICD 10 codes used to create control cohort

[Supplementary Table 2](#) Biobank cohort gender and Alzheimer's disease/Parkinson's disease demographics

[Supplementary Table 3](#) UKB diagnosis and disorders under study

[Supplementary Table 4](#) Proteomic biomarkers under study

[Supplementary Table 5](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for year of birth, Townsend deprivation index, and sex

[Supplementary Table 6](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for year of birth, Townsend deprivation index, and sex

[Supplementary Table 7](#) Interaction terms between endocrine, nutritional, metabolic, digestive system disorders and Alzheimer's disease polygenic risk score (excluding *APOE*)

[Supplementary Table 8](#) Interaction terms between endocrine, nutritional, metabolic, and digestive system disorders and Alzheimer's disease polygenic risk score

[Supplementary Table 9](#) Interaction terms between endocrine, nutritional, metabolic, digestive system disorders and Parkinson's disease polygenic risk score

[Supplementary Table 10](#) Biomarkers associated with Alzheimer's disease

[Supplementary Table 11](#) Biomarkers associated with Parkinson's disease

[Supplementary Table 12](#) Performance summary of different feature sets for Alzheimer's disease classification

[Supplementary Table 13](#) Performance summary of different feature sets for Parkinson's disease classification

[Supplementary Table 14](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for *APOE 4/4* status, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 15](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-score excluding *APOE*, *APOE 4/4* status, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 16](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-scores excluding *APOE*, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 17](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-score, *APOE 4/4* status, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 18](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-scores, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 19](#) Cox proportional hazards regression analysis of Alzheimer's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 20](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 21](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-scores, principal components 1-5, Townsend deprivation index, and sex

[Supplementary Table 22](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for *GBA1* (*G\_1\_155162560 + T\_1\_155235843*) status, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 23](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-scores, *GBA1* (*G\_1\_155162560 + T\_1\_155235843*) status, principal components 1-5, year of birth, Townsend deprivation index, and sex

[Supplementary Table 24](#) Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for *LRRK2* (*C\_12\_40220632 + G\_12\_40340400*) status, principal components 1-5, year of birth, Townsend deprivation index, and sex

**Supplementary Table 25 Cox proportional hazards regression analysis of Parkinson's disease and endocrine, nutritional, metabolic, and digestive system disorders ICD-10 codes adjusted for polygenic risk Z-scores, LRRK2 (C\_12\_40220632 + G\_12\_40340400) status, principal components 1-5, year of birth, Townsend deprivation index, and sex**

## References

1. M. I. Kurki, J. Karjalainen, P. Palta, T. P. Sipilä, K. Kristiansson, K. M. Donner, M. P. Reeve, H. Laivuori, M. Aavikko, M. A. Kaunisto, A. Loukola, E. Lahtela, H. Mattsson, P. Laiho, P. Della Briotta Parolo, A. A. Lehisto, M. Kanai, N. Mars, J. Rämö, T. Kiiskinen, H. O. Heyne, K. Veerapen, S. Rüeger, S. Lemmelä, W. Zhou, S. Ruotsalainen, K. Pärn, T. Hiekkalinna, S. Koskelainen, T. Paajanen, V. Llorens, J. Gracia-Tabuenca, H. Siirtola, K. Reis, A. G. Elnahas, B. Sun, C. N. Foley, K. Aalto-Setälä, K. Alasoo, M. Arvas, K. Auro, S. Biswas, A. Bizaki-Vallaskangas, O. Carpen, C.-Y. Chen, O. A. Dada, Z. Ding, M. G. Ehm, K. Eklund, M. Färkkilä, H. Finucane, A. Ganna, A. Ghazal, R. R. Graham, E. M. Green, A. Hakanen, M. Hautalahti, Å. K. Hedman, M. Hiltunen, R. Hinttala, I. Hovatta, X. Hu, A. Huertas-Vazquez, L. Huilaja, J. Hunkapiller, H. Jacob, J.-N. Jensen, H. Joensuu, S. John, V. Julkunen, M. Jung, J. Junntila, K. Kaarniranta, M. Kähönen, R. Kajanne, L. Kallio, R. Kälviäinen, J. Kaprio, FinnGen, N. Kerimov, J. Kettunen, E. Kilpeläinen, T. Kilpi, K. Klinger, V.-M. Kosma, T. Kuopio, V. Kurra, T. Laisk, J. Laukkonen, N. Lawless, A. Liu, S. Longerich, R. Mägi, J. Mäkelä, A. Mäkitie, A. Malarstig, A. Mannermaa, J. Maranville, A. Matakidou, T. Meretoja, S. V. Mozaffari, M. E. K. Niemi, M. Niemi, T. Niiranen, C. J. O. Donnell, M. E. Obeidat, G. Okafu, H. M. Ollila, A. Palomäki, T. Palotie, J. Partanen, D. S. Paul, M. Pelkonen, R. K. Pendergrass, S. Petrovski, A. Pitkäranta, A. Platt, D. Pulford, E. Punkka, P. Pussinen, N. Raghavan, F. Rahimov, D. Rajpal, N. A. Renaud, B. Riley-Gillis, R. Rodosthenous, E. Saarentaus, A. Salminen, E. Salminen, V. Salomaa, J. Schleutker, R. Serpi, H.-Y. Shen, R. Siegel, K. Silander, S. Siltanen, S. Soini, H. Soininen, J. H. Sul, I. Tachmazidou, K. Tasanen, P. Tienari, S. Toppila-Salmi, T. Tukiainen, T. Tuomi, J. A. Turunen, J. C. Ulirsch, F. Vaura, P. Virolainen, J. Waring, D. Waterworth, R. Yang, M. Nelis, A. Reigo, A. Metspalu, L. Milani, T. Esko, C. Fox, A. S. Havulinna, M. Perola, S. Ripatti, A. Jalanko, T. Laitinen, T. P. Mäkelä, R. Plenge, M. McCarthy, H. Runz, M. J. Daly, A. Palotie, FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).
2. C. A. Lane, J. Hardy, J. M. Schott, Alzheimer's disease. *Eur. J. Neurol.* **25**, 59–70 (2018).
3. E. Tolosa, A. Garrido, S. W. Scholz, W. Poewe, Challenges in the diagnosis of Parkinson's disease. *Lancet Neurol.* **20**, 385–397 (2021).
4. A. Gustavsson, N. Norton, T. Fast, L. Frölich, J. Georges, D. Holzapfel, T. Kirabali, P. Krolak-Salmon, P. M. Rossini, M. T. Ferretti, L. Lanman, A. S. Chadha, W. M. van der Flier, Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimers. Dement.* **19**, 658–670 (2023).
5. Z. Ou, J. Pan, S. Tang, D. Duan, D. Yu, H. Nong, Z. Wang, Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. *Front Public Health* **9**, 776847 (2021).

6. G. D. Rabinovici, Late-onset Alzheimer Disease. *Continuum* **25**, 14–33 (2019).
7. D. K. Simon, C. M. Tanner, P. Brundin, Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. *Clin. Geriatr. Med.* **36**, 1–12 (2020).
8. V. Bellou, L. Belbasis, I. Tzoulaki, E. Evangelou, J. P. A. Ioannidis, Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. *Parkinsonism Relat. Disord.* **23**, 1–9 (2016).
9. L. Migliore, F. Coppedè, Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics. *Nat. Rev. Neurol.* **18**, 643–660 (2022).
10. J. A. Santiago, J. A. Potashkin, The Impact of Disease Comorbidities in Alzheimer's Disease. *Front. Aging Neurosci.* **13**, 631770 (2021).
11. J. A. Santiago, V. Bottero, J. A. Potashkin, Biological and Clinical Implications of Comorbidities in Parkinson's Disease. *Front. Aging Neurosci.* **9**, 394 (2017).
12. A. H. Tan, S. Y. Lim, A. E. Lang, The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. *Nat. Rev. Neurol.* **18**, 476–495 (2022).
13. K. Kowalski, A. Mulak, Brain-Gut-Microbiota Axis in Alzheimer's Disease. *J. Neurogastroenterol. Motil.* **25**, 48–60 (2019).
14. J. Kang, M. Lee, M. Park, J. Lee, S. Lee, J. Park, A. Koyanagi, L. Smith, C. J. Nehs, D. K. Yon, T. Kim, Slow gut transit increases the risk of Alzheimer's disease: An integrated study of the bi-national cohort in South Korea and Japan and Alzheimer's disease model mice. *J. Advert. Res.*, doi: 10.1016/j.jare.2023.12.010 (2023).
15. J. H. Moon, Endocrine Risk Factors for Cognitive Impairment. *Endocrinol Metab (Seoul)* **31**, 185–192 (2016).
16. N. Charoenngam, T. Rittiphairoj, B. Ponvilawan, K. Prasongdee, Thyroid Dysfunction and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Front. Endocrinol.* **13**, 863281 (2022).
17. B. Chai, F. Gao, R. Wu, T. Dong, C. Gu, Q. Lin, Y. Zhang, Vitamin D deficiency as a risk factor for dementia and Alzheimer's disease: an updated meta-analysis. *BMC Neurol.* **19**, 284 (2019).
18. A. Pignolo, S. Mastrelli, C. Davì, V. Arnao, P. Aridon, F. A. Dos Santos Mendes, C. Gagliardo, M. D'Amelio, Vitamin D and Parkinson's Disease. *Nutrients* **14** (2022).
19. J. R. Colca, B. N. Finck, Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches. *Front Mol Biosci* **9**, 929328 (2022).
20. J. H. Kim, H. S. Lee, Y. H. Kim, M. J. Kwon, J.-H. Kim, C. Y. Min, D. M. Yoo, H. G. Choi, The Association Between Thyroid Diseases and Alzheimer's Disease in a National Health Screening Cohort in Korea. *Front. Endocrinol.* **13**, 815063 (2022).
21. L.-Y. Ma, B. Zhao, Y.-N. Ou, D.-D. Zhang, Q.-Y. Li, L. Tan, Association of thyroid disease with risks of dementia and cognitive impairment: A meta-analysis and systematic review. *Front. Aging Neurosci.*


- 15**, 1137584 (2023).
22. K. Han, B. Kim, S. H. Lee, M. K. Kim, A nationwide cohort study on diabetes severity and risk of Parkinson disease. *NPJ Parkinsons Dis* **9**, 11 (2023).
  23. H. Chohan, K. Senkevich, R. K. Patel, J. P. Bestwick, B. M. Jacobs, S. Bandres Ciga, Z. Gan-Or, A. J. Noyce, Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. *Mov. Disord.* **36**, 1420–1429 (2021).
  24. A. Athanasaki, K. Melanis, I. Tsantzali, M. I. Stefanou, S. Ntymenou, S. G. Paraskevas, T. Kalamatianos, E. Boutati, V. Lambadiari, K. I. Voumavourakis, G. Stranjalis, S. Giannopoulos, G. Tsivgoulis, G. P. Paraskevas, Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer's Disease: Review and Meta-Analysis. *Biomedicines* **10** (2022).
  25. J. Nowell, E. Blunt, D. Gupta, P. Edison, Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease. *Ageing Res. Rev.* **89**, 101979 (2023).
  26. Y. Zhao, Y. Sun, H.-F. Ji, L. Shen, Vitamin D levels in Alzheimer's and Parkinson's diseases: a meta-analysis. *Nutrition* **29**, 828–832 (2013).
  27. B. Konings, L. Villatoro, J. Van den Eynde, G. Barahona, R. Burns, M. McKnight, K. Hui, G. Yenokyan, J. Tack, P. J. Pasricha, Gastrointestinal syndromes preceding a diagnosis of Parkinson's disease: testing Braak's hypothesis using a nationwide database for comparison with Alzheimer's disease and cerebrovascular diseases. *Gut* **72**, 2103–2111 (2023).
  28. S. Yuan, L. Dan, Y. Zhang, J. Wu, J. Zhao, M. Kivipelto, J. Chen, J. F. Ludvigsson, X. Li, S. C. Larsson, Digestive System Diseases, Genetic Risk, and Incident Dementia: A Prospective Cohort Study. *Am. J. Prev. Med.* **66**, 516–525 (2024).
  29. Secure Anonymised Information Linkage Databank (SAIL Databank), *Population Data Science* (2019). <https://popdatasci.swan.ac.uk/centres-of-excellence/sail/>.
  30. B. W. Kunkle, B. Grenier-Boley, R. Sims, J. C. Bis, V. Damotte, A. C. Naj, A. Boland, M. Vronskaya, S. J. van der Lee, A. Amlie-Wolf, C. Bellenguez, A. Frizatti, V. Chouraki, E. R. Martin, K. Sleegers, N. Badarinarayanan, J. Jakobsdottir, K. L. Hamilton-Nelson, S. Moreno-Grau, R. Olaso, R. Raybould, Y. Chen, A. B. Kuzma, M. Hiltunen, T. Morgan, S. Ahmad, B. N. Vardarajan, J. Epelbaum, P. Hoffmann, M. Boada, G. W. Beecham, J.-G. Garnier, D. Harold, A. L. Fitzpatrick, O. Valladares, M.-L. Moutet, A. Gerrish, A. V. Smith, L. Qu, D. Bacq, N. Denning, X. Jian, Y. Zhao, M. Del Zompo, N. C. Fox, S.-H. Choi, I. Mateo, J. T. Hughes, H. H. Adams, J. Malamon, F. Sanchez-Garcia, Y. Patel, J. A. Brody, B. A. Dombroski, M. C. D. Naranjo, M. Daniilidou, G. Eiriksdottir, S. Mukherjee, D. Wallon, J. Uphill, T. Aspelund, L. B. Cantwell, F. Garzia, D. Galimberti, E. Hofer, M. Butkiewicz, B. Fin, E. Scarpini, C. Sarnowski, W. S. Bush, S. Meslage, J. Kornhuber, C. C. White, Y. Song, R. C. Barber, S. Engelborghs, S. Sordon, D. Voijnovic, P. M. Adams, R. Vandenberghe, M. Mayhaus, L. A. Cupples, M. S. Albert, P. P. De Deyn, W. Gu, J. J. Himali, D. Beekly, A. Squassina, A. M. Hartmann, A. Orellana, D. Blacker, E. Rodriguez-Rodriguez, S. Lovestone, M. E. Garcia, R. S. Doody, C. Munoz-Fernandez, R. Sussams, H. Lin, T. J. Fairchild, Y. A. Benito, C. Holmes, H. Karamujić-Čomić, M. P. Frosch, H. Thonberg, W. Maier, G. Roshchupkin, B. Ghetti, V. Giedraitis, A. Kawalia, S. Li, R. M. Huebinger, L. Kilander, S. Moebus, I. Hernández, M. I. Kamboh, R. Brundin, J. Turton, Q. Yang, M. J. Katz, L. Concari, J. Lord, A. S. Beiser, C. D. Keene, S. Helisalmi, I. Kloszewska, W. A. Kukull, A. M. Koivisto, A. Lynch, L. Tarraga, E. B. Larson, A.

Haapasalo, B. Lawlor, T. H. Mosley, R. B. Lipton, V. Solfrizzi, M. Gill, W. T. Longstreth Jr, T. J. Montine, V. Frisardi, M. Diez-Fairen, F. Rivadeneira, R. C. Petersen, V. Deramecourt, I. Alvarez, F. Salani, A. Ciaramella, E. Boerwinkle, E. M. Reiman, N. Fievet, J. I. Rotter, J. S. Reisch, O. Hanon, C. Cupidi, A. G. Andre Uitterlinden, D. R. Royall, C. Dufouil, R. G. Maletta, I. de Rojas, M. Sano, A. Brice, R. Cecchetti, P. S. George-Hyslop, K. Ritchie, M. Tsolaki, D. W. Tsuang, B. Dubois, D. Craig, C.-K. Wu, H. Soininen, D. Avramidou, R. L. Albin, L. Fratiglioni, A. Germanou, L. G. Apostolova, L. Keller, M. Koutroumani, S. E. Arnold, F. Panza, O. Gkatzima, S. Asthana, D. Hannequin, P. Whitehead, C. S. Atwood, P. Caffarra, H. Hampel, I. Quintela, Á. Carracedo, L. Lannfelt, D. C. Rubinsztein, L. L. Barnes, F. Pasquier, L. Fröhlich, S. Barral, B. McGuinness, T. G. Beach, J. A. Johnston, J. T. Becker, P. Passmore, E. H. Bigio, J. M. Schott, T. D. Bird, J. D. Warren, B. F. Boeve, M. K. Lupton, J. D. Bowen, P. Proitsi, A. Boxer, J. F. Powell, J. R. Burke, J. S. K. Kauwe, J. M. Burns, M. Mancuso, J. D. Buxbaum, U. Bonuccelli, N. J. Cairns, A. McQuillin, C. Cao, G. Livingston, C. S. Carlson, N. J. Bass, C. M. Carlsson, J. Hardy, R. M. Carney, J. Bras, M. M. Carrasquillo, R. Guerreiro, M. Allen, H. C. Chui, E. Fisher, C. Masullo, E. A. Crocco, C. DeCarli, G. Bisceglie, M. Dick, L. Ma, R. Duara, N. R. Graff-Radford, D. A. Evans, A. Hodges, K. M. Faber, M. Scherer, K. B. Fallon, M. Riemenschneider, D. W. Fardo, R. Heun, M. R. Farlow, H. Kölsch, S. Ferris, M. Leber, T. M. Foroud, I. Heuser, D. R. Galasko, I. Giegling, M. Gearing, M. Hüll, D. H. Geschwind, J. R. Gilbert, J. Morris, R. C. Green, K. Mayo, J. H. Growdon, T. Feulner, R. L. Hamilton, L. E. Harrell, D. Drichel, L. S. Honig, T. D. Cushion, M. J. Huentelman, P. Hollingworth, C. M. Hulette, B. T. Hyman, R. Marshall, G. P. Jarvik, A. Meggy, E. Abner, G. E. Menzies, L.-W. Jin, G. Leonenko, L. M. Real, G. R. Jun, C. T. Baldwin, D. Grozeva, A. Karydas, G. Russo, J. A. Kaye, R. Kim, F. Jessen, N. W. Kowall, B. Vellas, J. H. Kramer, E. Vardy, F. M. LaFerla, K.-H. Jöckel, J. J. Lah, M. Dichgans, J. B. Leverenz, D. Mann, A. I. Levey, S. Pickering-Brown, A. P. Lieberman, N. Klopp, K. L. Lunetta, H.-E. Wichmann, C. G. Lyketsos, K. Morgan, D. C. Marson, K. Brown, F. Martiniuk, C. Medway, D. C. Mash, M. M. Nöthen, E. Masliah, N. M. Hooper, W. C. McCormick, A. Daniele, S. M. McCurry, A. Bayer, A. N. McDavid, J. Gallacher, A. C. McKee, H. van den Bussche, M. Mesulam, C. Brayne, B. L. Miller, S. Riedel-Heller, C. A. Miller, J. W. Miller, A. Al-Chalabi, J. C. Morris, C. E. Shaw, A. J. Myers, J. Wilfang, S. O'Bryant, J. M. Olichney, V. Alvarez, J. E. Parisi, A. B. Singleton, H. L. Paulson, J. Collinge, W. R. Perry, S. Mead, E. Peskind, D. H. Cribbs, M. Rossor, A. Pierce, N. S. Ryan, W. W. Poon, B. Nacmias, H. Potter, S. Sorbi, J. F. Quinn, E. Sacchinelli, A. Raj, G. Spalletta, M. Raskind, C. Caltagirone, P. Bossù, M. D. Orfei, B. Reisberg, R. Clarke, C. Reitz, A. D. Smith, J. M. Ringman, D. Warden, E. D. Roberson, G. Wilcock, E. Rogaeva, A. C. Bruni, H. J. Rosen, M. Gallo, R. N. Rosenberg, Y. Ben-Shlomo, M. A. Sager, P. Mecocci, A. J. Saykin, P. Pastor, M. L. Cuccaro, J. M. Vance, J. A. Schneider, L. S. Schneider, S. Slifer, W. W. Seeley, A. G. Smith, J. A. Sonnen, S. Spina, R. A. Stern, R. H. Swerdlow, M. Tang, R. E. Tanzi, J. Q. Trojanowski, J. C. Troncoso, V. M. Van Deerlin, L. J. Van Eldik, H. V. Vinters, J. P. Vonsattel, S. Weintraub, K. A. Welsh-Bohmer, K. C. Wilhelmsen, J. Williamson, T. S. Wingo, R. L. Woltjer, C. B. Wright, C.-E. Yu, L. Yu, Y. Saba, A. Pilotto, M. J. Bullido, O. Peters, P. K. Crane, D. Bennett, P. Bosco, E. Coto, V. Boccardi, P. L. De Jager, A. Lleo, N. Warner, O. L. Lopez, M. Ingelsson, P. Deloukas, C. Cruchaga, C. Graff, R. Gwilliam, M. Fornage, A. M. Goate, P. Sanchez-Juan, P. G. Kehoe, N. Amin, N. Ertekin-Taner, C. Berr, S. Debette, S. Love, L. J. Launer, S. G. Younkin, J.-F. Dartigues, C. Corcoran, M. A. Ikram, D. W. Dickson, G. Nicolas, D. Campion, J. Tschanz, H. Schmidt, H. Hakonarson, J. Clarimon, R. Munger, R. Schmidt, L. A. Farrer, C. Van Broeckhoven, M. C O'Donovan, A. L. DeStefano, L. Jones, J. L. Haines, J.-F. Deleuze, M. J. Owen, V. Gudnason, R. Mayeux, V. Escott-Price, B. M. Psaty, A. Ramirez, L.-S. Wang, A. Ruiz, C. M. van Duijn, P. A. Holmans, S. Seshadri, J. Williams, P. Amouyel, G. D. Schellenberg, J.-C. Lambert, M. A. Pericak-Vance, Alzheimer Disease Genetics Consortium (ADGC), European Alzheimer's Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease Consortium (GERAD/PERADES), Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau,

- immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
31. M. A. Nalls, C. Blauwendraat, C. L. Vallerga, K. Heilbron, S. Bandres-Ciga, D. Chang, M. Tan, D. A. Kia, A. J. Noyce, A. Xue, J. Bras, E. Young, R. von Coelln, J. Simón-Sánchez, C. Schulte, M. Sharma, L. Krohn, L. Pihlstrøm, A. Siitonen, H. Iwaki, H. Leonard, F. Faghri, J. R. Gibbs, D. G. Hernandez, S. W. Scholz, J. A. Botia, M. Martinez, J.-C. Corvol, S. Lesage, J. Jankovic, L. M. Shulman, M. Sutherland, P. Tienari, K. Majamaa, M. Toft, O. A. Andreassen, T. Bangale, A. Brice, J. Yang, Z. Gan-Or, T. Gasser, P. Heutink, J. M. Shulman, N. W. Wood, D. A. Hinds, J. A. Hardy, H. R. Morris, J. Gratten, P. M. Visscher, R. R. Graham, A. B. Singleton, 23andMe Research Team, System Genomics of Parkinson’s Disease Consortium, International Parkinson’s Disease Genomics Consortium, Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
  32. J. A. Collister, X. Liu, L. Clifton, Calculating Polygenic Risk Scores (PRS) in UK Biobank: A Practical Guide for Epidemiologists. *Front. Genet.* **13**, 818574 (2022).
  33. C. C. Chang, C. C. Chow, L. C. Tellier, S. Vattikuti, S. M. Purcell, J. J. Lee, Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
  34. F. Delcò, A. Sonnenberg, Associations between hemorrhoids and other diagnoses. *Dis. Colon Rectum* **41**, 1534–41; discussion 1541–2 (1998).
  35. J. A. Heit, The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J. Thromb. Thrombolysis* **21**, 23–29 (2006).
  36. R. Cameron, M. M. Walker, M. Thuresson, B. Roelstraete, F. Sköldberg, O. Olén, N. J. Talley, J. F. Ludvigsson, Mortality risk increased in colonic diverticular disease: a nationwide cohort study. *Ann. Epidemiol.* **76**, 39–49 (2022).
  37. B. C. Lucey, J. C. Varghese, J. A. Soto, Spontaneous hemoperitoneum: causes and significance. *Curr. Probl. Diagn. Radiol.* **34**, 182–195 (2005).
  38. H. van Goor, Consequences and complications of peritoneal adhesions. *Colorectal Dis.* **9 Suppl 2**, 25–34 (2007).
  39. M. Falconi, P. Pederzoli, The relevance of gastrointestinal fistulae in clinical practice: a review. *Gut* **49 Suppl 4**, iv2–10 (2001).
  40. S. Gao, H. C. Hendrie, K. S. Hall, S. Hui, The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. *Arch. Gen. Psychiatry* **55**, 809–815 (1998).
  41. T. Pringsheim, N. Jette, A. Frolikis, T. D. L. Steeves, The prevalence of Parkinson’s disease: a systematic review and meta-analysis. *Mov. Disord.* **29**, 1583–1590 (2014).
  42. Y. A. Momtaz, T. A. Hamid, R. Ibrahim, Gastritis May Boost Odds of Dementia. *Am. J. Alzheimers. Dis. Other Demen.* **29**, 452–456 (2014).
  43. D. Baglietto-Vargas, J. Shi, D. M. Yaeger, R. Ager, F. M. LaFerla, Diabetes and Alzheimer’s disease crosstalk. *Neurosci. Biobehav. Rev.* **64**, 272–287 (2016).

44. M. N. Haan, Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. *Nat. Clin. Pract. Neurol.* **2**, 159–166 (2006).
45. Q. Xu, Y. Park, X. Huang, A. Hollenbeck, A. Blair, A. Schatzkin, H. Chen, Diabetes and risk of Parkinson's disease. *Diabetes Care* **34**, 910–915 (2011).
46. M. Doulberis, G. Kotronis, D. Gialamprinou, S. A. Polyzos, A. Papaefthymiou, P. Katsinelos, J. Kountouras, Alzheimer's disease and gastrointestinal microbiota; impact of infection involvement. *Int. J. Neurosci.* **131**, 289–301 (2021).
47. Y. Li, Y. Chen, L. Jiang, J. Zhang, X. Tong, D. Chen, W. Le, Intestinal Inflammation and Parkinson's Disease. *Aging Dis.* **12**, 2052–2068 (2021).
48. K. Y. Kim, K. Y. Shin, K.-A. Chang, GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. *Cells* **12** (2023).
49. M. Szeliga, Peroxiredoxins in Neurodegenerative Diseases. *Antioxidants (Basel)* **9** (2020).
50. S. Karantzoulis, J. E. Galvin, Distinguishing Alzheimer's disease from other major forms of dementia. *Expert Rev. Neurother.* **11**, 1579–1591 (2011).

**Figure 1 - Study design**



The initial phase of our study utilized clinical data sourced from electronic medical records (EMR) alongside genetic and proteomic data obtained from the UK Biobank. Quality control procedures were rigorously applied to clinical and genetic datasets, including filtering for individuals of European ancestry, exclusion of related samples, and extraction of 155 ICD-10 codes representing diagnoses related to digestive, endocrine, nutritional, and metabolic disorders. Proteomic data underwent normalization of protein expression levels as part of quality control measures. The culmination of this phase involved the application of a Cox proportional hazards model, examination of polygenic risk scores, and development of a generalized linear model (GLM). These analyses collectively contributed to the construction of a multi-classification predictive model for Alzheimer's disease (AD) and Parkinson's disease (PD). Phase II of our study entailed validating these findings using data from the Secure Anonymised Information Linkage (SAIL) and FinnGen biobanks.

Figure 2





Figure 3



**Overview tables**

Table 1. Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with AD risk

Table 2. Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with PD risk

Table 3. Time-Stratified Cox Regression model for AD

Table 4. Time-Stratified Cox Regression model for PD

Table 5. Proteomic biomarker comparison in isolated AD cases vs. cases with digestive, endocrine, metabolic, and nutritional conditions

Table 6. Proteomic biomarker comparison in isolated PD cases vs. cases with digestive, endocrine, metabolic, and nutritional conditions

Table 1

Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with AD risk											
Prior_ICD10_code	Prior_ICD10_code_Description	Dataset	Neurodegenerative disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	P_VAL_FDR_Corrected	N_pairs	n	rejected
E85	amyloidosis, other/unspecified	Finngen	AD	3.98	1.20	13.27	2.44E-02	3.65E-02	17		TRUE
	amyloidosis	UKB		2.57	1.34	4.94	4.72E-03	2.61E-02	9	182	TRUE
K04	diseases of pulp and periapical tissues	Finngen	AD	2.83	1.67	4.82	1.17E-04	2.68E-04	267		TRUE
	diseases of pulp and periapical tissues	UKB		1.44	1.11	1.87	6.21E-03	3.26E-02	57	3,365	TRUE
E78	disorders of lipoprotein metabolism and other lipidaemias	Finngen	AD	5.71	4.76	6.85	1.55E-78	1.46E-76	2,522.00		TRUE
	disorders of lipoprotein metabolism and other lipidaemias	UKB		1.18	1.09	1.27	1.53E-05	1.34E-04	1090	53,797	TRUE
E83	disorders of mineral metabolism	Finngen	AD	6.63	3.51	12.51	5.26E-09	2.10E-08	68.00		TRUE
	disorders of mineral metabolism	UKB		1.32	1.08	1.62	7.75E-03	3.88E-02	94	4,435	TRUE
K29	other gastritis (incl. Duodenitis)	Finngen	AD	2.40	1.53	3.77	1.35E-04	3.06E-04	416.00		TRUE
	gastritis and duodenitis	UKB		1.20	1.09	1.32	1.45E-04	1.17E-03	523	27,914	TRUE
K64	haemorrhoids and perianal venous thrombosis	Sail	AD	0.37	0.27	0.51	6.83E-10	8.64E-09	39	11,389	TRUE
	haemorrhoids and perianal venous thrombosis	UKB		0.69	0.59	0.80	6.94E-07	8.10E-06	186	20,162	TRUE
E10	Type 1 diabetes, wide definition * (includes E10)	Finngen	AD	2.46	1.63	3.70	1.60E-05	4.22E-05	272		TRUE
	insulin-dependent diabetes mellitus	Sail		1.78	1.48	2.13	4.29E-10	5.68E-09	118	6,668	TRUE
	insulin-dependent diabetes mellitus	UKB		3.09	2.45	3.90	1.77E-21	1.86E-19	73	1,633	TRUE
E11	Type 2 diabetes, wide definition*(includes E11)	Finngen	AD	4.02	3.28	4.92	2.54E-41	8.54E-40	2641		TRUE
	non-insulin-dependent diabetes mellitus	Sail		1.27	1.19	1.35	3.77E-14	8.43E-13	1052	72,913	TRUE
	non-insulin-dependent diabetes mellitus	UKB		1.47	1.33	1.63	1.19E-14	4.18E-13	476	19,048	TRUE
K20	oesophagitis	Finngen	AD	4.23	2.20	8.13	1.58E-05	4.16E-05	77.00		TRUE
	oesophagitis	UKB		1.28	1.10	1.49	1.63E-03	1.00E-02	175	8,660	TRUE
A04	other bacterial intestinal infections	Finngen	AD	2.56	1.22	5.37	1.27E-02	2.01E-02	255.00		TRUE
	other bacterial intestinal infections	Sail		1.37	1.14	1.65	6.29E-04	2.95E-03	117	6,202	TRUE
	other bacterial intestinal infections	UKB		1.51	1.21	1.89	2.35E-04	1.76E-03	81	3,585	TRUE
E87	other disorders of fluid, electrolyte and acid-base balance	Finngen	AD	10.04	7.24	13.93	2.11E-43	8.07E-42	600.00		TRUE
	other disorders of fluid, electrolyte and acid-base balance	UKB		1.51	1.34	1.70	6.43E-12	1.35E-10	312	11,313	TRUE
K59	other functional intestinal disorders	Finngen	AD	4.37	3.30	5.80	1.02E-24	1.51E-23	886.00		TRUE
	other functional intestinal disorders	Sail		1.19	1.09	1.29	9.59E-05	5.47E-04	529	29,639	TRUE
	other functional intestinal disorders	UKB		1.55	1.40	1.73	3.55E-16	1.86E-14	394	15,596	TRUE
K52	other noninfective gastroenteritis and colitis	Finngen	AD	2.53	1.40	4.57	2.15E-03	3.98E-03	300.00		TRUE
	other non-infective gastro-enteritis and colitis	Sail		1.36	1.22	1.50	4.97E-09	5.56E-08	373	23,128	TRUE
	other non-infective gastro-enteritis and colitis	UKB		1.37	1.20	1.56	1.75E-06	1.84E-05	250	12,984	TRUE
E14	unspecified diabetes mellitus	Sail	AD	1.49	1.19	1.88	6.05E-04	2.89E-03	73	4,470	TRUE
	unspecified diabetes mellitus	UKB		1.53	1.33	1.75	1.21E-09	1.58E-08	224	8,733	TRUE
E55	vitamin d deficiency	Finngen	AD	13.48	4.76	38.22	9.94E-07	3.16E-06	26.00		TRUE
	vitamin d deficiency	UKB		1.95	1.57	2.41	9.97E-10	1.50E-08	87	2,405	TRUE
E86	volume depletion	Finngen	AD	10.65	4.09	27.71	1.24E-06	3.88E-06	161.00		TRUE
	volume depletion	UKB		1.78	1.52	2.10	3.26E-12	8.57E-11	153	4,911	TRUE

AD: Alzheimer's disease

UKB: UK Biobank

SAIL: Secure Anonymised Information Linkage Databank

Prior\_ICD10\_code: initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders

ci\_min: Confidence interval minimum

ci\_max: Confidence interval maximum

P\_VAL: p-value

P\_VAL\_FDR\_Corrected: p-value after False Discovery Rate corrected

N\_pairs: Number of individuals identified with both ICD-10 code and neurodegenerative disease outcome

Table 1

Table 2

Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with PD risk											
Prior_ICD10_code	Prior_ICD10_code_Description	Dataset	Neurodegenerative disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	P_VAL_FDR_Corrected	N_pairs	n	rejected
K57	diverticular disease of intestine	Sail	PD	0.75	0.69	0.81	1.74E-11	2.82E-10	555.00	70,198.00	TRUE
	diverticular disease of intestine	UKB		0.69	0.62	0.77	6.24E-11	2.04E-09	354.00	34,801.00	TRUE
K30	functional dyspepsia	Finngen	PD	2.72	1.96	3.76	1.95E-09	1.21E-08	86.00		TRUE
	dyspepsia	UKB		1.34	1.13	1.60	8.51E-04	9.26E-03	135.00	8,811.00	TRUE
E10	insulin-dependent diabetes mellitus	Sail	PD	1.59	1.31	1.93	3.36E-06	2.48E-05	101.00	6,668.00	TRUE
	insulin-dependent diabetes mellitus	UKB		2.65	2.02	3.48	2.44E-12	1.20E-10	53.00	1,608.00	TRUE
E11	Type 2 diabetes, wide definition*(Includes E11)	Finngen	PD	2.04	1.75	2.39	2.06E-19	3.38E-18	421.00		TRUE
	non-insulin-dependent diabetes mellitus	UKB		1.21	1.08	1.36	1.36E-03	1.33E-02	330.00	18,815.00	TRUE
K63	other diseases of intestine	Sail	PD	0.84	0.73	0.97	1.51E-02	4.71E-02	205.00	25,877.00	TRUE
	other diseases of intestine	UKB		0.69	0.59	0.80	1.34E-06	2.20E-05	183.00	19,139.00	TRUE
K66	other disorders of peritoneum	Sail	PD	0.70	0.53	0.93	1.32E-02	4.21E-02	48.00	7,406.00	TRUE
	other disorders of peritoneum	UKB		0.63	0.45	0.87	5.81E-03	4.42E-02	35.00	4,612.00	TRUE
K59	other functional intestinal disorders	Finngen	PD	3.19	2.46	4.14	2.02E-18	3.02E-17	178.00		TRUE
	other functional intestinal disorders	UKB		1.56	1.38	1.76	4.81E-13	4.71E-11	301.00	15,431.00	TRUE

Table 3

Time-Stratified Cox Regression model for AD												
ICD10_code	ICD10_code_description	ICD10_diagnosis_range	Neurodegenerative disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	N_pairs	n	P_VAL_FDR_CC	rejected	
A04	Other Bacterial Intestinal Infections	1-5	AD	2.12	1.28	3.53	3.63E-03	15	434	6.60E-03	TRUE	
A04	Other Bacterial Intestinal Infections	All	AD	1.51	1.21	1.89	2.35E-04	81	3585	3.35E-04	TRUE	
E10	Insulin-Dependent Diabetes Mellitus	1-5	AD	3.13	1.85	5.29	2.05E-05	14	325	5.11E-05	TRUE	
E10	Insulin-Dependent Diabetes Mellitus	5-10	AD	3.08	1.94	4.90	1.96E-06	18	398	9.78E-06	TRUE	
E10	Insulin-Dependent Diabetes Mellitus	10-15	AD	3.68	2.32	5.85	3.55E-08	18	318	1.60E-07	TRUE	
E10	Insulin-Dependent Diabetes Mellitus	All	AD	3.09	2.45	3.90	1.77E-21	73	1633	3.55E-20	TRUE	
E11	Non-Insulin-Dependent Diabetes Mellitus	5-10	AD	1.32	1.11	1.58	1.91E-03	128	5496	4.78E-03	TRUE	
E11	Non-Insulin-Dependent Diabetes Mellitus	10-15	AD	1.82	1.53	2.17	1.59E-11	133	4023	2.86E-10	TRUE	
E11	Non-Insulin-Dependent Diabetes Mellitus	All	AD	1.47	1.33	1.63	1.19E-14	476	19048	7.96E-14	TRUE	
E14	Unspecified Diabetes Mellitus	5-10	AD	1.79	1.13	2.85	1.36E-02	18	827	2.47E-02	TRUE	
E14	Unspecified Diabetes Mellitus	10-15	AD	2.28	1.76	2.94	4.16E-10	59	1803	3.74E-09	TRUE	
E14	Unspecified Diabetes Mellitus	All	AD	1.53	1.33	1.75	1.21E-09	224	8733	3.02E-09	TRUE	
E16	Other Disorders Of Pancreatic Internal Secretion	1-5	AD	3.52	2.41	5.15	7.75E-11	27	374	1.55E-09	TRUE	
E16	Other Disorders Of Pancreatic Internal Secretion	5-10	AD	1.87	1.21	2.91	5.12E-03	20	525	1.02E-02	TRUE	
E16	Other Disorders Of Pancreatic Internal Secretion	10-15	AD	2.69	1.34	5.38	5.23E-03	8	180	1.18E-02	TRUE	
E16	Other Disorders Of Pancreatic Internal Secretion	All	AD	2.23	1.75	2.83	5.27E-11	69	1637	1.76E-10	TRUE	
E53	Deficiency Of Other B Group Vitamins	1-5	AD	2.33	1.66	3.27	9.65E-07	34	700	3.86E-06	TRUE	
E53	Deficiency Of Other B Group Vitamins	5-10	AD	1.74	1.08	2.80	2.29E-02	17	509	3.81E-02	TRUE	
E53	Deficiency Of Other B Group Vitamins	All	AD	1.78	1.40	2.27	2.61E-06	68	1939	4.75E-06	TRUE	
E55	Vitamin D Deficiency	1-5	AD	2.35	1.80	3.06	2.47E-10	56	1198	2.47E-09	TRUE	
E55	Vitamin D Deficiency	All	AD	1.95	1.57	2.41	9.97E-10	87	2405	2.85E-09	TRUE	
E66	Obesity	All	AD	0.85	0.74	0.96	9.29E-03	260	22619	9.29E-03	TRUE	
E78	Disorders Of Lipoprotein Metabolism And Other Lipidaemias	5-10	AD	1.48	1.29	1.70	3.33E-08	212	8983	3.33E-07	TRUE	
E78	Disorders Of Lipoprotein Metabolism And Other Lipidaemias	10-15	AD	1.44	1.27	1.63	4.43E-09	288	12012	2.66E-08	TRUE	
E78	Disorders Of Lipoprotein Metabolism And Other Lipidaemias	All	AD	1.18	1.09	1.27	1.53E-05	1090	53797	2.56E-05	TRUE	
E83	Disorders Of Mineral Metabolism	1-5	AD	1.64	1.22	2.21	9.34E-04	45	1522	2.08E-03	TRUE	
E83	Disorders Of Mineral Metabolism	All	AD	1.32	1.08	1.62	7.75E-03	94	4435	8.16E-03	TRUE	
E85	Amyloidosis	1-5	AD	3.59	1.61	8.00	1.75E-03	6	81	3.50E-03	TRUE	
E85	Amyloidosis	All	AD	2.57	1.34	4.94	4.72E-03	9	182	5.55E-03	TRUE	
E86	Volume Depletion	1-5	AD	1.90	1.48	2.44	5.01E-07	63	1678	2.50E-06	TRUE	
E86	Volume Depletion	5-10	AD	1.89	1.32	2.71	5.28E-04	30	795	1.56E-03	TRUE	
E86	Volume Depletion	10-15	AD	2.09	1.28	3.41	3.30E-03	16	374	9.91E-03	TRUE	
E86	Volume Depletion	All	AD	1.78	1.52	2.10	3.26E-12	153	4911	1.63E-11	TRUE	
E87	Other Disorders Of Fluid, Electrolyte And Acid-Base Balance	1-5	AD	1.52	1.27	1.81	3.99E-06	128	4059	1.14E-05	TRUE	
E87	Other Disorders Of Fluid, Electrolyte And Acid-Base Balance	5-10	AD	1.72	1.37	2.16	3.78E-06	75	1965	1.51E-05	TRUE	
E87	Other Disorders Of Fluid, Electrolyte And Acid-Base Balance	10-15	AD	1.92	1.34	2.75	3.70E-04	30	786	1.33E-03	TRUE	
E87	Other Disorders Of Fluid, Electrolyte And Acid-Base Balance	All	AD	1.51	1.34	1.70	6.43E-12	312	11313	2.57E-11	TRUE	
K04	Diseases Of Pulp And Periapical Tissues	1-5	AD	2.41	1.20	4.82	1.31E-02	8	305	1.87E-02	TRUE	
K04	Diseases Of Pulp And Periapical Tissues	All	AD	1.44	1.11	1.87	6.21E-03	57	3365	6.90E-03	TRUE	
K20	Oesophagitis	1-5	AD	1.62	1.16	2.28	4.88E-03	34	1399	8.14E-03	TRUE	
K20	Oesophagitis	5-10	AD	1.51	1.15	1.99	3.18E-03	52	2290	7.06E-03	TRUE	
K20	Oesophagitis	All	AD	1.28	1.10	1.49	1.63E-03	175	8660	2.03E-03	TRUE	
K29	Gastritis And Duodenitis	5-10	AD	1.32	1.13	1.55	5.47E-04	160	7742	1.56E-03	TRUE	
K29	Gastritis And Duodenitis	10-15	AD	1.31	1.09	1.57	3.89E-03	120	5837	1.00E-02	TRUE	
K29	Gastritis And Duodenitis	All	AD	1.20	1.09	1.32	1.45E-04	523	27914	2.23E-04	TRUE	
K52	Other Non-Infective Gastro-Enteritis And Colitis	5-10	AD	2.31	1.82	2.93	6.20E-12	69	2086	1.24E-10	TRUE	
K52	Other Non-Infective Gastro-Enteritis And Colitis	10-15	AD	1.36	1.08	1.70	7.92E-03	77	3697	1.43E-02	TRUE	
K52	Other Non-Infective Gastro-Enteritis And Colitis	All	AD	1.37	1.20	1.56	1.75E-06	250	12984	3.50E-06	TRUE	
K59	Other Functional Intestinal Disorders	1-5	AD	1.55	1.30	1.85	1.27E-06	127	4476	4.22E-06	TRUE	
K59	Other Functional Intestinal Disorders	5-10	AD	1.70	1.40	2.07	8.75E-08	105	3464	5.83E-07	TRUE	

Table 3

Time-Stratified Cox Regression model for AD												
ICD10_code	ICD10_code_description	ICD10_diagnosis_range	Neurodegenerative disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	N_pairs	n	P_VAL_FDR_CC	rejected	
K59	Other Functional Intestinal Disorders	10-15	AD	1.41	1.10	1.82	7.32E-03	61	2512	1.43E-02	TRUE	
K59	Other Functional Intestinal Disorders	All	AD	1.55	1.40	1.73	3.55E-16	394	15596	3.55E-15	TRUE	
K64	Haemorrhoids And Perianal Venous Thrombosis	1-5	AD	0.41	0.29	0.58	2.60E-07	34	5880	1.73E-06	TRUE	
K64	Haemorrhoids And Perianal Venous Thrombosis	All	AD	0.69	0.59	0.80	6.94E-07	186	20162	1.54E-06	TRUE	
K66	Other Disorders Of Peritoneum	1-5	AD	0.49	0.28	0.86	1.28E-02	12	1668	1.87E-02	TRUE	
K66	Other Disorders Of Peritoneum	All	AD	0.59	0.44	0.81	8.77E-04	41	4636	1.17E-03	TRUE	

AD: Alzheimer's disease  
 ICD10\_code: initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders  
 ICD10\_diagnosis\_range: Number of years from the initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders (ICD-10 code) to the occurrence of neurodegenerative disease outcome  
 ci\_min: Confidence interval minimum  
 ci\_max: Confidence interval maximum  
 P\_VAL: p-value  
 N\_pairs: Number of individuals identified with both ICD-10 code and neurodegenerative disease outcome  
 n: Number of individuals Identified with ICD10\_code  
 P\_VAL\_FDR\_Corrected: p-value after False Discovery Rate corrected

Table 4

Time-Stratified Cox Regression model for PD										
ICD10_code	ICD10_code_description	ICD10_diagnosis_range	Neurodegenerative disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	N_pairs	n	P_VAL_FDR_CC rejected
E10	insulin-dependent diabetes mellitus	5-10	PD	3.08	1.89	5.04	7.15E-06	16	396	4.29E-05 TRUE
E10	insulin-dependent diabetes mellitus	10-15	PD	2.53	1.36	4.71	3.39E-03	10	310	1.02E-02 TRUE
E10	insulin-dependent diabetes mellitus	All	PD	2.65	2.02	3.48	2.44E-12	53	1608	1.46E-11 TRUE
E11	non-insulin-dependent diabetes mellitus	5-10	PD	1.41	1.16	1.70	4.19E-04	112	5480	8.38E-04 TRUE
E11	non-insulin-dependent diabetes mellitus	10-15	PD	1.40	1.13	1.74	2.03E-03	86	3976	8.10E-03 TRUE
E11	non-insulin-dependent diabetes mellitus	All	PD	1.21	1.08	1.36	1.36E-03	330	18815	1.63E-03 TRUE
E14	unspecified diabetes mellitus	1-5	PD	1.94	1.17	3.22	1.06E-02	15	623	1.58E-02 TRUE
E14	unspecified diabetes mellitus	5-10	PD	2.66	1.76	4.01	3.04E-06	23	832	3.65E-05 TRUE
E14	unspecified diabetes mellitus	10-15	PD	1.94	1.45	2.60	8.17E-06	46	1790	9.80E-05 TRUE
E14	unspecified diabetes mellitus	All	PD	1.61	1.39	1.86	1.81E-10	197	8658	5.44E-10 TRUE
E16	other disorders of pancreatic internal secretion	1-5	PD	1.89	1.04	3.42	3.54E-02	11	358	4.73E-02 TRUE
E16	other disorders of pancreatic internal secretion	5-10	PD	1.94	1.17	3.22	1.06E-02	15	520	1.81E-02 TRUE
E16	other disorders of pancreatic internal secretion	All	PD	1.84	1.36	2.47	6.76E-05	44	1602	1.16E-04 TRUE
E53	deficiency of other b group vitamins	1-5	PD	2.04	1.34	3.10	8.81E-04	22	688	2.64E-03 TRUE
E53	deficiency of other b group vitamins	All	PD	1.72	1.30	2.29	1.88E-04	48	1907	2.81E-04 TRUE
E66	obesity	1-5	PD	0.63	0.47	0.83	1.45E-03	47	6561	2.95E-03 TRUE
E66	obesity	All	PD	0.82	0.71	0.94	5.86E-03	211	22453	5.86E-03 TRUE
K30	dyspepsia	5-10	PD	1.84	1.39	2.44	1.90E-05	50	2480	7.61E-05 TRUE
K30	dyspepsia	All	PD	1.34	1.13	1.60	8.51E-04	135	8811	1.13E-03 TRUE
K57	diverticular disease of intestine	1-5	PD	0.60	0.48	0.75	8.54E-06	77	10132	5.12E-05 TRUE
K57	diverticular disease of intestine	5-10	PD	0.68	0.56	0.83	1.19E-04	104	10867	2.85E-04 TRUE
K57	diverticular disease of intestine	All	PD	0.69	0.62	0.77	6.24E-11	354	34801	2.50E-10 TRUE
K59	other functional intestinal disorders	1-5	PD	1.51	1.23	1.86	8.27E-05	94	4443	3.31E-04 TRUE
K59	other functional intestinal disorders	5-10	PD	1.62	1.29	2.03	3.70E-05	76	3435	1.11E-04 TRUE
K59	other functional intestinal disorders	10-15	PD	1.61	1.22	2.12	7.90E-04	51	2502	4.74E-03 TRUE
K59	other functional intestinal disorders	All	PD	1.56	1.38	1.76	4.81E-13	301	15431	5.77E-12 TRUE
K63	other diseases of intestine	1-5	PD	0.61	0.45	0.83	1.47E-03	42	5726	2.95E-03 TRUE
K63	other diseases of intestine	5-10	PD	0.74	0.57	0.95	1.67E-02	62	6182	2.23E-02 TRUE
K63	other diseases of intestine	10-15	PD	0.70	0.52	0.94	1.84E-02	44	4008	4.40E-02 TRUE
K63	other diseases of intestine	All	PD	0.69	0.59	0.80	1.34E-06	183	19139	2.69E-06 TRUE
K64	haemorrhoids and perianal venous thrombosis	1-5	PD	0.39	0.27	0.57	1.01E-06	27	5873	1.22E-05 TRUE
K64	haemorrhoids and perianal venous thrombosis	5-10	PD	0.66	0.47	0.92	1.55E-02	34	4640	2.23E-02 TRUE
K64	haemorrhoids and perianal venous thrombosis	All	PD	0.59	0.50	0.71	3.62E-09	136	20006	8.69E-09 TRUE
K66	other disorders of peritoneum	1-5	PD	0.34	0.16	0.72	4.79E-03	7	1663	8.21E-03 TRUE
K66	other disorders of peritoneum	All	PD	0.63	0.45	0.87	5.81E-03	35	4612	5.86E-03 TRUE

PD: Parkinson's disease

ICD10\_code: initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders

ICD10\_diagnosis\_range: Number of years from the initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders (ICD-10 code) to the occurrence of neurodegenerative disease outcome

ci\_min: Confidence interval minimum

ci\_max: Confidence interval maximum

P\_VAL: p-value

N\_pairs: Number of individuals identified with both ICD-10 code and neurodegenerative disease outcome

n: Number of individuals Identified with ICD10\_code

P\_VAL\_FDR\_CORRECTED: p-value after False Discovery Rate corrected







Table 5

tcn2	Transcobalamin-2	p130708	Non-insulin-Dependent Diabetes Mellitus	0.057		0.17	2.71	568	455	115	7.48e-03	5.22e-02	FALSE
tcn2	Transcobalamin-2	p131654	Other Disorders Of Peritoneum	0.076		0.29	2.90	568	558	12	1.80e-02	7.14e-02	FALSE
tcn2	Transcobalamin-2	p130706	Insulin-Dependent Diabetes Mellitus	0.073		0.32	3.03	568	552	18	6.94e-03	5.08e-02	FALSE



Table 6

Proteomic biomarker comparison in isolated PD cases vs. cases with digestive, endocrine, metabolic, and nutritional conditions																
Olink_marker_being_compared	Olink_marker_definition	ICD10_Code	ICD10_Code_definition	Average Olink_marker level in individuals diagnosed with only PD (PD)	Average Olink_marker level in individuals diagnosed with both PD and ICD-10 code (PD + ICD-10)	T-Statistic (PD + ICD-10 vs. PD)	Degrees of Free AD_size	AD_ICD10_size	P_Value	P_VAL_FDR_CORRECTED	FDR_CORRECTED_rejected					
Tyrosine-protein kinase Mer	merk	p131600	dyspepsia	0.11	0.07	-0.84	629	594	37	4.03E-01	6.53E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p131648	other diseases of intestine	0.11	0.09	-0.58	629	569	62	5.61E-01	7.55E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p131636	diverticular disease of intestine	0.11	0.11	0.15	629	487	144	8.82E-01	9.40E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p131640	other functional intestinal disorders	0.11	0.12	0.42	629	427	204	6.78E-01	8.34E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p130714	unspecified diabetes mellitus	0.11	0.13	0.60	629	573	58	5.50E-01	7.55E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p130792	obesity	0.11	0.15	1.07	629	551	80	2.90E-01	7.89E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p131654	deficiency of other b group vitamins	0.10	0.21	1.77	629	600	21	8.53E-02	3.07E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p131654	other disorders of peritoneum	0.11	0.25	1.78	629	621	10	1.07E-01	3.53E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p130708	non-insulin-dependent diabetes mellitus	0.10	0.16	1.94	629	527	104	5.43E-02	2.25E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p130718	other disorders of pancreatic internal secretion	0.10	0.25	2.34	629	606	25	2.74E-02	1.69E-01	FALSE				
Tyrosine-protein kinase Mer	merk	p130705	insulin-dependent diabetes mellitus	0.10	0.28	2.62	629	615	16	1.86E-02	1.34E-01	FALSE				
Desmoglein-2	dsq2	p130708	non-insulin-dependent diabetes mellitus	0.04	-0.05	-2.45	620	518	104	1.57E-02	1.33E-01	FALSE				
Desmoglein-2	dsq2	p130714	unspecified diabetes mellitus	0.03	-0.06	-1.84	620	565	57	7.09E-02	2.69E-01	FALSE				
Desmoglein-2	dsq2	p130792	obesity	0.03	-0.02	-1.35	620	544	78	1.80E-01	4.63E-01	FALSE				
Desmoglein-2	dsq2	p130770	deficiency of other b group vitamins	0.03	-0.02	-1.14	620	594	28	2.64E-01	5.68E-01	FALSE				
Desmoglein-2	dsq2	p131600	dyspepsia	0.03	0.00	-0.55	620	588	34	5.84E-01	7.78E-01	FALSE				
Desmoglein-2	dsq2	p131650	haemorrhoids and perianal venous thrombosis	0.03	0.01	-0.49	620	552	70	6.27E-01	8.21E-01	FALSE				
Desmoglein-2	dsq2	p131636	diverticular disease of intestine	0.02	0.04	0.66	620	481	141	5.07E-01	7.09E-01	FALSE				
Desmoglein-2	dsq2	p131648	other diseases of intestine	0.02	0.06	0.96	620	561	61	3.40E-01	6.45E-01	FALSE				
Desmoglein-2	dsq2	p130718	other disorders of pancreatic internal secretion	0.02	0.09	1.05	620	597	25	3.05E-01	6.11E-01	FALSE				
Desmoglein-2	dsq2	p131640	other functional intestinal disorders	0.01	0.05	1.52	620	420	202	1.29E-01	3.87E-01	FALSE				
Desmoglein-2	dsq2	p131654	other disorders of peritoneum	0.02	0.18	1.55	620	613	9	1.59E-01	4.33E-01	FALSE				
Desmoglein-2	dsq2	p130706	insulin-dependent diabetes mellitus	0.02	0.25	2.47	620	606	16	2.55E-02	1.67E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130770	deficiency of other b group vitamins	0.15	0.08	-0.82	631	602	31	4.20E-01	6.53E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131636	diverticular disease of intestine	0.16	0.14	-0.39	631	488	145	6.94E-01	8.40E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131600	dyspepsia	0.15	0.13	-0.24	631	596	37	8.11E-01	9.20E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130792	obesity	0.15	0.15	-0.01	631	552	81	9.91E-01	9.92E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131654	other disorders of peritoneum	0.15	0.17	0.09	631	624	9	9.28E-01	9.61E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131640	other disorders of intestinal disorders	0.14	0.16	-0.41	631	427	206	8.53E-01	8.81E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131650	haemorrhoids and perianal venous thrombosis	0.14	0.22	1.15	631	561	72	2.54E-01	5.54E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p131648	other diseases of intestine	0.14	0.26	1.67	631	570	63	9.99E-02	3.41E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130718	other disorders of pancreatic internal secretion	0.14	0.27	2.01	631	607	26	5.46E-02	2.25E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130706	insulin-dependent diabetes mellitus	0.14	0.46	2.61	631	616	17	1.83E-02	1.34E-01	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130708	non-insulin-dependent diabetes mellitus	0.12	0.29	3.00	631	527	106	3.08E-03	5.55E-02	FALSE				
Interleukin-1 receptor-like 1	ilrl1	p130714	unspecified diabetes mellitus	0.13	0.39	3.92	631	575	58	1.99E-04	2.87E-02	TRUE				
Neural cell adhesion molecule 1	ncam1	p130792	obesity	0.13	-0.03	-3.12	628	550	80	2.42E-03	4.97E-02	TRUE				
Neural cell adhesion molecule 1	ncam1	p130714	unspecified diabetes mellitus	0.12	-2.97	628	571	59	4.02E-03	6.43E-02	FALSE					
Neural cell adhesion molecule 1	ncam1	p130708	non-insulin-dependent diabetes mellitus	0.12	0.03	-2.45	628	525	105	1.55E-02	1.33E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131600	dyspepsia	0.11	0.01	-1.81	628	595	35	7.80E-02	2.88E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131636	diverticular disease of intestine	0.12	0.06	-1.58	628	485	145	1.15E-01	3.67E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p130770	deficiency of other b group vitamins	0.11	0.05	-0.81	628	600	30	4.26E-01	6.53E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p130706	insulin-dependent diabetes mellitus	0.11	0.04	-0.74	628	613	17	4.68E-01	6.87E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131640	other functional intestinal disorders	0.10	0.11	0.43	628	426	204	6.67E-01	8.34E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131654	other disorders of peritoneum	0.10	0.18	0.51	628	621	9	6.26E-01	8.21E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131648	other diseases of intestine	0.10	0.14	0.74	628	567	63	4.63E-01	6.87E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p130718	other disorders of pancreatic internal secretion	0.10	0.20	1.23	628	604	26	2.29E-01	5.15E-01	FALSE				
Neural cell adhesion molecule 1	ncam1	p131650	haemorrhoids and perianal venous thrombosis	0.10	0.17	1.52	628	559	71	1.32E-01	3.87E-01	FALSE				

PD: Parkinson's disease

P\_VAL\_FDR\_CORRECTED: p-value after False Discovery Rate corrected